Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPX-115
- Development stage
- Phase 3
- Lead developer
- Tego Science
- Modality
- Cell Therapies
- Administration
- Intra-tendinous
01
Overview
TPX-115 is an allogeneic dermal-derived fibroblast cell therapy developed by Tego Science for the treatment of partial-thickness rotator cuff tears. It is administered via intra-tendinous injection and aims to promote tendon repair in patients who have not responded to conservative treatments. The therapy utilizes allogeneic fibroblasts, which are intended to replace or support damaged tissue, potentially improving structural and functional outcomes in rotator cuff injuries. Clinical trials have progressed through phase 1/2 in Korea and are currently in phase 2b/3, with a U.S. FDA-approved phase 2 trial underway[1][3][4][7].
Beyond the preview
Go deeper on TPX-115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPX-115.